Europese Unie - Nederlands - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplasmata van de borst - antineoplastische middelen - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - osteoporose - calcium homeostase - sondelbay is indicated in adults. behandeling van osteoporose bij postmenopauzale vrouwen en bij mannen met een verhoogd risico op fracturen. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. de behandeling van osteoporose in verband met de aanhoudende systemische glucocorticoïden therapie bij vrouwen en mannen met een verhoogd risico op fracturen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Europese Unie - Nederlands - EMA (European Medicines Agency)

theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - calcium homeostase - behandeling van osteoporose bij postmenopauzale vrouwen met een verhoogd risico op fracturen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostase - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostase - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

cheplapharm arzneimittel gmbh ziegelhof 24 17489 greifswald (duitsland) - calciumcarbonaat (e 170) 2500 mg/stuk samenstelling overeenkomend met ; calcium (ca2+) 1000 mg/stuk ; cholecalciferol concentraat, poedervorm 8 mg/stuk samenstelling overeenkomend met ; cholecalciferol 20 µg/stuk - kauwtablet - citroensmaakstof 051124a firmenich ; gelatine (e 441) ; isomalt (e 953) ; magnesiumstearaat (e 470b) ; maÏszetmeel ; mono- en diglyceriden van vetzuren (e 471) ; povidon (e 1201) ; saccharose ; sojaboonolie, gedeeltelijk gehydreerd ; sucralose (e 955) ; tocoferol, dl-alfa (e 307) ; xylitol (e 967), - calcium, combinations with vitamin d and/or other drugs

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

euro registratie collectief b.v. - calciumcarbonaat (e 170) samenstelling overeenkomend met ; calcium (ca2+) - kauwtablet - aspartaam (e 951) ; isomalt (e 953) ; magnesiumstearaat (e 470b) ; mono- en diglyceriden van vetzuren (e 471) ; povidon (e 1201) ; sinaasappelsmaakstof ; sorbitol (d-)(e 420), - calcium carbonate

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

reckitt benckiser healthcare b.v. siriusdreef 14 2132 wt hoofddorp - calciumcarbonaat (e 170) 187,5 mg/stuk ; natriumalginaat (e 401) 250 mg/stuk ; natriumwaterstofcarbonaat (e 500 (ii)) 106,5 mg/stuk - kauwtablet - acesulfaam kalium (e 950) ; aspartaam (e 951) ; azorubine (e 122) ; carmellose natrium (e 466) ; copovidon ; macrogol 20000 ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; pepermuntsmaakstof af 1971 alexander flavours ; xylitol (e 967), acesulfaam kalium (e 950) ; aspartaam (e 951) ; azorubine (e 122) ; carmellose natrium (e 466) ; copovidon ; macrogol 20000 ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; pepermuntsmaakstof af 1971 alexander flavours ; xylitol (e 967), - alginic acid

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

carbamazepine 100 mg/stuk - tablet - allurarood ac aluminium lak (e 129) ; croscarmellose natrium (e 468) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd ; siliciumdioxide (e 551)